

## PUBBLICAZIONI – Dott.ssa Devizzi Lilli

1. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.  
Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, **Devizzi L**. *Int J Radiat Oncol Biol Phys*. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015 Dec 17. PMID: 26972651
2. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.  
Zinzani PL, Rigacci L, Cox MC, **Devizzi L**, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U. *Leuk Lymphoma*. 2015 Jun;56(6):1671-6. doi: 10.3109/10428194.2014.964702. Epub 2014 Nov 19. PMID: 25241999
3. 1:Lenalidomide monotherapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational multicenter retrospective study in daily clinical practice.  
Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U. *Leuk Lymphoma*. 2014 Sep 20:1-21. [Epub ahead of print] PMID: 25241999 IF: 2.605 2014
4. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.  
Conconi A, Raderer M, Franceschetti S, Devizzi L, Ferreri AJ, Magagnoli M, Arcaini L, Zinzani PL, Martinelli G, Vitolo U, Kiesewetter B, Porro E, Stathis A, Gaidano G, Cavalli F, Zucca E. *Br J Haematol*. 2014 Jul;166(1):69-76. doi: 10.1111/bjh.12845. Epub 2014 Mar 27.
5. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.  
Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. *Bone Marrow Transplant*. 2014 Apr;49(4):485-91. doi: 10.1038/bmt.2013.214. Epub 2014 Jan 20. PMID: 24442244 IF 3.466 2014
6. Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. *Am J Hematol*. 2013 Aug 12. IF 4,003 - 2012
7. Devizzi L, Guidetti A, Seregini E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM. Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y Ibritumomab Tiuxetan for Patients . With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. *J Clin Oncol*. 2013 Aug 10;31(23):2974-6 IF 18,038 - 2012
8. Longoni P, Milanese M, Di Nicola M, Devizzi L, Carrabba M, Arienti F, Ravagnani F, Tarella C, Montefusco V, Gianni A, Corradini P, Magni M. Successful second autologous engraftment after long duration storage of hematopoietic stem cells. *Bone Marrow Transplant*. 2013 May 27 IF 3,541 - 2012
9. Ferreri AJ, Govi S, Raderer M, Mulè A, Andriani A, Caracciolo D, Devizzi L, Ilariucci F, Luminari S, Viale E, Müllauer L, Dell'Oro S, Arcidiacono PG, Ponzoni M, Patti C. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicentre phase 2 trial. *Blood*. 2012 Nov 1;120(18):3858-60. IF 9.898 - 2011
10. Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Ravagnani F, Gianni AM. Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma. *Am J Blood Res*. 2012;2(2):105-12 IF 0
11. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. *Br J Haematol*. 2012 Jul;158(1):108-19. IF 4,941 - 2011
12. Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. *Cancer*. 2011 Nov 15;117(22):5074-84. IF

13. Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortelazzo S. CLIP1: anew prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). *Ann Hematol.* 2011 Apr;90(4):401-8. IF 2,688 2010
14. Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). *Ann Oncol.* 2011 Mar;22(3):689-95 IF 6,452 - 2010
15. Mirabile A, Devizzi L, Gianni AM, Cabras A, Carbone A. MALT lymphoma and Kaposi sarcoma in an HIV-negative patient. *Am J Hematol.* 2010 Oct;85(10):815-7. IF 2,61 - 2009
16. Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. *Leuk Lymphoma.* 2010 Jul;51(7):1251-9. IF 2,397 - 2009
17. Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, Matteucci P, Gianni AM. Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. *Bone Marrow Transplant.* 2010 Jun;45(6):1119-20. IF 4,531 - 2009
18. Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregini E, Gianni MA, Bombardieri E. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). *Eur J Nucl Med Mol Imaging.* 2009 Nov;36(11):1745-57 IF 4,532 - 2008
19. Magni M, Di Nicola M, Testi A, Cabras A, Devizzi L, Guidetti A, Matteucci P, Viviani S, Bonfante V, Carniti C, Ricca I, Carbone A, Carlo-Stella C, Gianni AM. Radioimmunotherapy and secondary leukemia: a case report. *Leuk Res.* 2010 Jan;34(1):e1-4 IF 2,358 - 2009
20. Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Tarella C, Benedetti F, Martelli M, Patti C, Parvis G, Rambaldi A, Barbui T, Gianni AM. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. *Bone Marrow Transplant.* 2009 Mar;43(6):509-11. IF 3,4 - 2008
21. Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregini E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. *J Clin Oncol.* 2008 Nov 10;26(32):5175-82. IF 15,484 - 2007
22. Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, Cabras A, Anichini A, Gianni AM. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. *Blood.* 2009 Jan 1;113(1):18-27. IF 10,432 - 2008
23. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL).
24. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. *Blood.* 2008 Apr 15;111(8):4004-13. IF 10,896 - 2007
25. Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, Hossfeld D, Pratt G, Dell'Olio M, Choo SP, Bociek RG, Radford J, Lade S, Gianni AM, Zucca E, Cavalli F, Seymour JF; International Extranodal Lymphoma Study Group. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International
26. Extranodal Lymphoma Study Group. *Ann Oncol.* 2008 Feb;19(2):233-41. IF 4,875 - 2007
27. Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregini E, Gianni AM,

Bombardieri E. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. *Cancer Biother Radiopharm.* 2007 IF 1,763 - 2006 .

28. Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). *Leukemia.* 2007 Aug;21(8):1802-11. IF 6,146 - 2006
29. Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. *Br J Haematol.* 2004 Sep;126(6):815-20. IF 3,267 - 2003
30. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. *Blood.* 2004 Apr 1;103(7):2474-9. IF 10,12 - 2003
31. Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. *Blood.* 2003 Oct 15;102(8):2741-5. IF 10,12 - 2003
32. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. *J Clin Oncol.* 2003 Jan 5;21(2):266-72. IF 9,868 - 2002
33. Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. *Haematologica.* 2002 Dec;87(12):1258-64. PubMed PMID: 12495899. IF 3,216 - 2002
34. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, López-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F; International Extranodal Lymphoma Study Group. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. *Blood.* 2003 Apr 1;101(7):2489-95. Epub 2002 Nov 27. PubMed PMID: 12456507. IF 9,273 - 2003
36. Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L, Gianni AM, Cavalli F, Barbui T; International Extranodal Lymphoma Study Group (IELSG). The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. *Br J Haematol.* 2002 Jul;118(1):218-28. PubMed PMID: 12100151. **IF 2,815 - 2002**
37. Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. *Eur J Haematol Suppl.* 2001 Jul;64:51-5. PubMed PMID: 11486403. **IF 1,672 - 2001**
38. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli G, Tarella C, Pileri A, Bonadonna G, Gianni AM. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. *Blood.* 2000 Aug 1;96(3):864-9. PubMed PMID: 10910898. **IF 8,977 - 2000**
39. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. *J Clin Oncol.* 2000 Jul;18(13):2615-9. PubMed PMID: 10893294. **IF 8,773 - 2000**
40. Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. *Cancer J Sci Am.* 1999 Sep-Oct;5(5):275-82. PubMed PMID: 10526668. **IF 2,742 - 1999**

41. Maffioli LS, Castellani MR, Bombardieri E, Devizzi L, Draisma A, Pauwels E. Changing biodistribution of gallium during G-CSF treatment in non- Hodgkin's disease. *Eur J Nucl Med.* 1999 Jan;26(1):68-9. PubMed PMID: 10048953. **IF 3,239 - 1999**
42. Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. *Br J Haematol.* 1998 Nov;103(2):533-5. PubMed PMID: 9827930. **IF 3,209 - 1998**
43. Gasparini M, Bombardieri E, Castellani M, Tondini C, Maffioli L, Devizzi L, Gerundini P. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. *J Nucl Med.* 1998 Sep;39(9):1586-90. PubMed PMID: 9744348. **IF 3,064 - 1998**
44. Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, Devizzi L, Verderio P, Valagussa P, Bonadonna G. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. *Br J Cancer.* 1998 Mar;77(6):992-7. PubMed PMID: 9528846; PubMed Central PMCID: PMC2150083. **IF 3,036 - 1998**
45. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. *J Clin Oncol.* 1997 Feb;15(2):528-34. PubMed PMID: 9053474. **IF 7,878 - 1997**
46. Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M, Valagussa P, Bombardieri E, Santoro A, Bonadonna G. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. *Ann Oncol.* 1997;8 Suppl 1:53-6. PubMed PMID: 9187430. **IF 2,548 - 1997**
47. Balzarotti M, Tondini C, Bonfante V, Devizzi L, Viviani S, Fornier M, Santoro A. Lack of carboplatin activity in malignant lymphomas. *Eur J Cancer.* 1996 Dec;32A(13):2370-1. PubMed PMID: 9038628. **IF 2,191 - 1996**
48. Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Vinorelbine: a new promising drug in Hodgkin's disease. *Leuk Lymphoma.* 1996 Aug;22(5-6):409-14. Review. PubMed PMID: 8882953. **IF 1,134 - 1996**
49. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. *J Clin Oncol.* 1996 May;14(5):1421-30. PubMed PMID: 8622055. **IF 7,881 - 1996**
50. Zanini M, Viviani S, Santoro A, Soncini F, Bonfante V, Devizzi L, Villani F, Castellani MR, Negretti E, Zucali R, et al. Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage). *Int J Radiat Oncol Biol Phys.* 1994 Nov 15;30(4):813-9. PubMed PMID: 7525516. **IF 2,321 - 1994**
51. Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P, Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. *Ann Oncol.* 1994 Nov;5(9):817-20. PubMed PMID: 7531487. **IF 1,914 - 1994**
52. Pellegris G, Lombardo C, Cantoni A, Devizzi L, Balzarotti M. Study of the HLA-DP beta 1 locus by the polymerase chain reaction technique in patients with Hodgkin's disease. *Tumori.* 1993 Apr 30;79(2):133-6. PubMed PMID: 8346566. **IF 0 - 1993**
53. Casali P, Pastorino U, Azzarelli A, Bertulli R, Zucchinelli P, Devizzi L, Santoro A. Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. *Cancer Chemother Pharmacol.* 1993;31 Suppl 2:S228-32. PubMed PMID: 8453704. **IF 1,041 - 1993**
54. Casali P, Pastorino U, Zucchinelli P, Devizzi L, Azzarelli A, Quagliuolo V, Bignami P, Santoro A, Bonadonna G. Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas. *Ann Oncol.* 1992 Apr;3 Suppl 2:S125-6. PubMed PMID: 1622854. **IF 1,917 - 1992**
55. Bonfante V, Santoro A, Viviani S, Zucali R, Devizzi L, Zanini M, Tesoro Tess JD, Valagussa P, Banfi A, Bonadonna G. Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. *Eur J Cancer.* 1992;29A(1):24-9. PubMed PMID: 1445741. **IF 2,191 - 1993**